RCKT vs. DRNA, RCUS, AUPH, YMAB, HRTX, ROIV, ITCI, ASND, CERE, and IONS
Should you be buying Rocket Pharmaceuticals stock or one of its competitors? The main competitors of Rocket Pharmaceuticals include Dicerna Pharmaceuticals (DRNA), Arcus Biosciences (RCUS), Aurinia Pharmaceuticals (AUPH), Y-mAbs Therapeutics (YMAB), Heron Therapeutics (HRTX), Roivant Sciences (ROIV), Intra-Cellular Therapies (ITCI), Ascendis Pharma A/S (ASND), Cerevel Therapeutics (CERE), and Ionis Pharmaceuticals (IONS). These companies are all part of the "medical" sector.
Rocket Pharmaceuticals (NASDAQ:RCKT) and Dicerna Pharmaceuticals (NASDAQ:DRNA) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, community ranking, analyst recommendations, earnings, risk, profitability and media sentiment.
98.4% of Rocket Pharmaceuticals shares are owned by institutional investors. Comparatively, 78.9% of Dicerna Pharmaceuticals shares are owned by institutional investors. 31.1% of Rocket Pharmaceuticals shares are owned by company insiders. Comparatively, 10.2% of Dicerna Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Rocket Pharmaceuticals presently has a consensus price target of $51.25, indicating a potential upside of 93.25%. Given Rocket Pharmaceuticals' higher probable upside, equities analysts clearly believe Rocket Pharmaceuticals is more favorable than Dicerna Pharmaceuticals.
Dicerna Pharmaceuticals received 79 more outperform votes than Rocket Pharmaceuticals when rated by MarketBeat users. However, 72.39% of users gave Rocket Pharmaceuticals an outperform vote while only 62.28% of users gave Dicerna Pharmaceuticals an outperform vote.
Rocket Pharmaceuticals has a net margin of 0.00% compared to Dicerna Pharmaceuticals' net margin of -64.53%. Rocket Pharmaceuticals' return on equity of -53.10% beat Dicerna Pharmaceuticals' return on equity.
Dicerna Pharmaceuticals has higher revenue and earnings than Rocket Pharmaceuticals. Dicerna Pharmaceuticals is trading at a lower price-to-earnings ratio than Rocket Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Rocket Pharmaceuticals has a beta of 1.13, meaning that its stock price is 13% more volatile than the S&P 500. Comparatively, Dicerna Pharmaceuticals has a beta of 0.8, meaning that its stock price is 20% less volatile than the S&P 500.
In the previous week, Rocket Pharmaceuticals had 10 more articles in the media than Dicerna Pharmaceuticals. MarketBeat recorded 10 mentions for Rocket Pharmaceuticals and 0 mentions for Dicerna Pharmaceuticals. Rocket Pharmaceuticals' average media sentiment score of 0.49 beat Dicerna Pharmaceuticals' score of 0.00 indicating that Rocket Pharmaceuticals is being referred to more favorably in the media.
Summary
Rocket Pharmaceuticals beats Dicerna Pharmaceuticals on 11 of the 16 factors compared between the two stocks.
Get Rocket Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for RCKT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RCKT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Rocket Pharmaceuticals Competitors List
Related Companies and Tools
